Business

According to Pulmatrix, the Lung Cancer Initiative at Johnson & Johnson will pay $7.2 million up front plus a $2 million milestone payment for an option "to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception." The $2 million milestone payment will be due on completion of a Phase 1b study of RV1162/PUR1800 … [Read more...] about Pulmatrix announces license agreement with J&J’s Lung Cancer Initiative

CF PharmTech, which says it is developing a variety of OINDPs, announced that it has closed a Series E financing round  that will be used to support development of its pipeline products. The $90 million round was led by Shanghai-based New Alliance Capital. In August 2017, the company said that it had raised $65 million in a Series D round to support development … [Read more...] about CF PharmTech gets $90 million in latest financing round for inhaled drug development

Inhaled drug developer Savara announced that it has entered into a definitive agreement for a private placement of common stock, pre-funded warrants, and milestone warrants with an expected $26.8 million in gross proceeds from sales of the common stock and pre-funded warrants and a potential of up to $75 million if all milestone warrants are exercised. The private … [Read more...] about Savara announces $26.8 million private placement

Aerosurf inhaled surfactant developer Windtree Therapeutics has announced the completion of a $26.4 million private placement of common stock and warrants. Net proceeds were approximately $23 million. Windtree is developing several inhaled drugs delivered via the company's proprietary Aerosol Delivery System (ADS). In addition to Aerosurf inhaled KL4 surfactant, … [Read more...] about Windtree Therapeutics announces completion of $26.4 million private placement

According to UCB, Nayzilam midazolam nasal spray will be available in the US as of December 2, 2019. UCB acquired the nasal spray from Proximagen in April 2018, and the FDA approved Nayzilam for the treatment of seizure clusters in epilepsy patients 12 years old and older in May 2019. The company said that Nayzilam is expected to cost $40 for a box containing two … [Read more...] about UCB announces US launch of Nayzilam midazolam nasal spray

DPI developer Iconovo has announced that the Japanese Patent Office has granted the company a patent covering its ICOres dry powder inhaler. According to Iconovo, Sweden and European patents related to ICOres have already been issued. In March 2019, Iconovo announced that CBC Corporation was taking over development responsibilities from Amneal Pharmaceuticals for … [Read more...] about Iconovo gets Japanese patent for ICOres DPI